New-generation antidepressants do not produce clinically significant improvements in depression

In this open access publication in PLoS it is

...suggest that, compared with placebo, the new-generation antidepressants do not produce clinically significant improvements in depression in patients who initially have moderate or even very severe depression, but show significant effects only in the most severely depressed patients. The findings also show that the effect for these patients seems to be due to decreased responsiveness to placebo, rather than increased responsiveness to medication. Given these results, the researchers conclude that there is little reason to prescribe new-generation antidepressant medications to any but the most severely depressed patients unless alternative treatments have been ineffective. In addition, the finding that extremely depressed patients are less responsive to placebo than less severely depressed patients but have similar responses to antidepressants is a potentially important insight into how patients with depression respond to antidepressants and placebos that should be investigated further.


Here is the original article.
You don't need to be special to read it, since it is published in an Open Access journal.

More like this

I've not had time to thoroughly read this yet. But on the heels of another study published a few weeks ago (I blogged on it here) showing that SSRIs have little therapeutic effect if you include the (unflattering) clinical trials the industry had previously hidden, PLOS Medicine now publishes a…
[This is a revised, expanded version of the original heads-up I put up last night.] A large new meta-analysis of SSRI antidepressant trials concludes that the drugs have essentially no therapeutic effect at all. The study, in PLOS Medicine today, comes on the heels of another study published a few…
Another study purports to find that, for most people, Prozac and the other members of the antidepressant family of pharmaceuticals are no better than sugar pills. Expect Big Pharma to object, but not too loudly. At least, don't expect them to expend too much effort and money denouncing the findings…
Late last month, I put up a quick post, New-generation antidepressants do not produce clinically significant improvements in depression, that addressed a PLoS published metastudy of interest. I was careful to use the phrasing from the paper as the title of my post, and to provide only the author'…

The press coverage of this has been misleading, according to this pharmacy student (I found him via SciBlog's own Terra Sigillatta). http://secundumartem.blogspot.com/2008/02/some-depressing-news.html

Quickly -- the studies were not original studies, but meta examinations of previous studies. The previous studies only showed the effects of 4-6 months in mildly depressed patients. They don't cover severely depressed nor long term use.

Yes, it is a meta study (which is still a study) and it focuses on a subset of treatments and conditions, as do all studies. I have not seen the press coverage, but I'm not surprised to find that it is misleading.

As the director of Novus Medical Detox, I often see patients who are on alcohol or opioids, central nervous system depressants, also taking antidepressants. When they detox they find they don't need the antidepressants.

This is good news because a Swedish study showed that 52% of the 2006 suicides by women on antidepressants. Since antidepressants work no better than placebos and are less effective than exercise in dealing with depression.

There is a prescription drug epidemic and these are leaders in the list of terribe abuses.

Steve Hayes
http://novusdetox.com